Sarah Lawrence College

DigitalCommons@SarahLawrence
Human Genetics Theses

The Joan H. Marks Graduate Program in
Human Genetics

5-2019

Assessing The Impact Of Predictive Testing Protocols On
Provider Burden For Huntington's Disease
Paige Ernste
Sarah Lawrence College

Abigail Patenaude
Sarah Lawrence College

Follow this and additional works at: https://digitalcommons.slc.edu/genetics_etd
Part of the Genetics Commons, and the Other Genetics and Genomics Commons

Recommended Citation
Ernste, Paige and Patenaude, Abigail, "Assessing The Impact Of Predictive Testing Protocols On Provider
Burden For Huntington's Disease" (2019). Human Genetics Theses. 57.
https://digitalcommons.slc.edu/genetics_etd/57

This Thesis - Open Access is brought to you for free and open access by the The Joan H. Marks Graduate Program
in Human Genetics at DigitalCommons@SarahLawrence. It has been accepted for inclusion in Human Genetics
Theses by an authorized administrator of DigitalCommons@SarahLawrence. For more information, please contact
alester@sarahlawrence.edu.

ASSESSING THE IMPACT OF PREDICTIVE TESTING
PROTOCOLS ON PROVIDER BURDEN
FOR HUNTINGTON’S DISEASE

by
Paige Ernste
and
Abigail Patenaude

Submitted in partial completion of the Master of Science Degree at Sarah Lawrence
College, May 2019

Abstract
Predictive testing for HD creates a potentially significant psychological burden on patients and
their families, and in turn, the emotional strain of working with at-risk individuals may take a toll
on providers. Protocols have been established by the HDSA that emphasize the importance of
genetic counseling and support for individuals undergoing testing. Recently, the HDSA’s
guidelines have switched from recommending a 3-visit protocol to a 2-visit protocol. Little is
known about the effect of this change on genetic service providers, their practice, their
perception of the patient experience, or the impact of their choice of protocol in terms of the
burden on providers. This study examined the impact of such testing from the provider’s
perspective. Providers involved in the HD predictive testing process at 43 Centers of Excellence
across the country were invited to participate in a survey examining protocol use and emotional
burden. Of the 54 respondents, 37% reported changing their protocol in light of the HDSA’s
recommendations while 33% reported always having used the 2-visit protocol. Almost half
(48%, n=26/54) of providers reported having feelings of emotional burden related to their work
with predictive testing; the most frequent causes being “emotional overextension” and
“exhaustion.” There was no difference in the emotional burden reported by providers who made
the protocol switch and providers who did not. This study provides evidence that a 2-visit
protocol for HD predictive testing has been widely adopted by practicing providers, and that
many providers switched in response to the HDSA’s update to their guidelines. Results also
suggest that there is a high emotional burden related to this type of work, regardless of the type
of protocol used.

Key terms: Huntington’s disease, predictive testing, provider burden
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Introduction
Genetic testing for late-onset disorders such as Huntington’s disease (HD) has been
available for more than two decades (Paneque et al, 2012). Predictive genetic testing, described
as a testing option for healthy people at risk of developing HD (Craufurd et al, 2014), has the
potential to cause emotional anxiety for these individuals. Because of the psychological
sequelae associated with learning that one is likely to develop HD, genetic counseling is
regarded as a crucial component of the predictive testing process. Studies have shown that the
experience of providing predictive testing itself can be stressful for providers, resulting in, most
commonly, compassion stress and fatigue (Bernhardt et al, 2009). While protocols have been
established and revised over time by the Huntington’s Disease Society of America (HDSA) in
order to provide the best outcomes for patients, there have not been any studies to determine
which protocol is least taxing for medical providers.
HD is a hereditary neurodegenerative disorder that affects 1/10,000 individuals in the
United States. It is caused by a trinucleotide repeat expansion in the HTT gene (HDCRG, 1993).
This expansion results in a long and unstable fragment with potential for genetic anticipation,
especially when paternally inherited. Symptom onset is typically observed in the fourth or fifth
decade of life (Chandler et al, 1960), however, onset and progression are variable. In the later
stages of the disease, affected individuals experience a decline in cognitive ability, develop
difficulty speaking and swallowing, are usually bedridden, and are totally dependent on others
for all of their needs. These symptoms can persist for 10 to 25 years until death occurs
(Sorensen & Fenger, 1992), typically the result of complications such as malnutrition or
aspiration pneumonia. There is no approved cure or treatment for HD at this time, and
consequently, there is no medical benefit to undergoing predictive testing.
Many experts have argued that the decision to undergo predictive testing is complex,
emotionally challenging, and likely to cause anxiety among participants and their family
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members, who may struggle to adapt after receiving their results (Dufrasne et al, 2010; Tibben,
2007; Crozier, 2015). Other concerns associated with testing include the potential for genetic
discrimination, implications for family members, and potential psychological dysfunction, all of
which may create a substantial burden for patients. Conflicting evidence has been presented on
these psychological effects and while recent studies have reported that catastrophic reactions to
test results are rare (Crozier, 2015; Paulsen et al, 2005; Nance, 2016), other studies have
shown higher suicidal tendencies among the at-risk population (Robins Wahlin et al, 2000). For
these reasons, although little is known about how genetic counseling impacts preparation for
and living with the results of genetic testing (Paneque, 2012), pre-test counseling has typically
been a required part of the protocol to allow patients adequate time and information to make
what is potentially a significant and irreversible decision (Craufurd et al, 2014).
The HDSA has endorsed guidelines for predictive genetic testing that HD centers are
encouraged to follow. These guidelines specifically emphasize recommendations for
counseling. The initial guidelines, introduced by the HDSA in 1989 and revised again in 2003,
required that the HD predictive testing process be spread out over three visits (HDSA, 2003).
The first two visits were to consist of a neurological evaluation, genetic counseling session, and
a psychological assessment. Only after the neurologist, genetic counselor, and psychologist
agreed that the patient was equipped to handle information about their gene status would the
patient be recommended to move forward with testing. Results would be disclosed on the third
visit. Updated guidelines produced in 2016 reduce the recommended number of visits from
three to two, only requiring one visit before test results would be disclosed (HDSA, 2016).
Genetic and psychological support services have become standard of care in the
management of HD families. There are currently 43 HD Centers of Excellence across the nation
that follow guidelines written by the HDSA to provide care programs for families choosing to
undergo testing. Eligibility and classification criteria for HD Centers of Excellence include the
clinic’s ability to “provide comprehensive diagnostic and therapeutic services” with onsite
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personnel responsible for services in neurology, psychiatry, psychology, genetic counseling and
testing, social services, physical therapy, occupational therapy, speech-language services,
nutritional/dietary services, and direct participation in HD clinical trials (HDSA, 2018). Guidelines
strongly encourage physicians to refer appropriate applicants to one of these designated
predictive testing centers (HDSA, 2016).
Because of the range of services required by an HD Center of Excellence, a variety of
different providers are often involved in the predictive testing process: neurologists,
psychiatrists, genetic counselors, social workers, and nurse practitioners. HDSA guidelines
emphasize the importance of extensive genetic counseling for individuals considering testing.
While many studies exist that examine the effects of predictive genetic testing on patients
(Almqvist et al, 1999; Crozier 2015; Erwin et al, 2010; Nance, 2016; Paneque, 2012; Paulsen et
al, 2005; Robins Wahlin et al, 2000; Paulsen et al, 2013), little is known about the degree of
burden placed on genetics professionals as a result of working with patients involved in
predictive testing, particularly for HD.
Literature exploring burnout among physicians shows that burnout is a common serious
condition with devastating personal and professional consequences (Romani & Ashkar, 2014;
Everall & Paulson, 2004). Shanafelt et al, 2012 reported 45.8% of physicians in the United
States having at least one symptom of burnout. Another study by the European General
Practice Research Network Burnout Study Group, which included 1,400 family physicians in 12
European countries, revealed that 43% of respondents scored high for emotional exhaustion,
35% for depersonalization, and 32% for low personal accomplishment, while 12% of participants
suffered from burnout in all three dimensions (Soler et al, 2008).
There is currently one study examining distress and burnout among genetics
professionals, which found that genetic service providers experience various types of distress
that may be risk factors for burnout and professional dissatisfaction, citing the most prevalent
examples as compassion stress, the burden of professional responsibility, negative patient
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regard, inauthenticity, and concerns about informational bias (Bernhardt et al, 2009). Pletcher et
al, 2002 identified several external factors potentially contributing to burnout: reimbursement
issues, lack of institutional support, low-earning potential, and uncertainty about the future of
clinical genetics. The aim of our study was to determine internal factors that may impact the
burden, as measured by the Maslach Burnout Inventory (Maslach & Jackson, 1981),
experienced by genetic service providers involved in HD predictive testing using the 2- or 3-visit
testing protocol. No studies currently exist that examine the experiences of genetic counselors
and other medical personnel working in HD centers, particularly in light of the recently revised
protocol which reduces the number of required visits from three to two.

Methods
Study Design
We created a survey through SurveyMonkey, composed of demographic, multiple choice, and
open-ended questions. Healthcare providers were asked about the protocol for HD predictive
testing currently in place at their institution, and changes that occurred in response to the
change in HDSA guidelines in 2016. One set of multiple-choice questions consisted of “agree”
or “disagree” options and others employed a 3-point Likert scale with the options of “increase,”
“decrease,” or “no change.” These questions were intended to measure provider burden related
to the HD protocol used by each provider at their respective institution subsequent to the 2016
protocol change. Study participants were able to provide more detailed opinions of each
protocol in open ended questions. Provider burden was measured by a modified form of the
Maslach Burnout Inventory-Human Services Survey for Medical Personnel (MBI-HSS (MP)),
which addresses three issues: emotional exhaustion, depersonalization, and personal
accomplishment. Each participant was asked to identify whether or not they felt an emotional
burden, defined as “the feeling of being emotionally stressed, sometimes in the form of feeling
the pain of others or feeling inner guilt,” as a result of their work by indicating if they experienced
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any of the following: emotional overextension, exhaustion, impersonal feelings,
depersonalization of work, incompetence at work, and feelings of lack of achievement. A
complete copy of the participant questionnaire is provided in Appendix A.

Study Participants
A sample of 66 participants were recruited from the 43 Centers of Excellence and six HDSA
partner centers in the United States that offer predictive testing for HD. All participants in this
study were volunteers. This study was approved by the Sarah Lawrence College Institutional
Review Board on October 11th, 2019 and was endorsed by the HDSA. Service providers were
eligible to participate if they currently provide predictive testing for HD as part of their practice.
Potential study participants were recruited through the HD Centers of Excellence and partner
centers by an email invitation detailing study information and providing a link to the
questionnaire distributed through SurveyMonkey. An informed consent form was presented prior
to the start of the questionnaire which contained information about the purpose of the study,
benefits and risks of participating, the voluntary nature of participation, and contact information
for the researchers. Participants were free to skip questions and could withdraw from the survey
at any point.

Inclusion and Exclusion Criteria
We received 66 survey responses. In order for a survey participant to be included in the study,
they must be directly involved in HD predictive testing and have completed the questionnaire. Of
the 66 responses, 54 were included in the data analysis. Data from one survey participant who
reported no direct involvement in predictive testing for HD was excluded. Data from 11 survey
participants who did not complete the survey were also excluded.
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Data Analysis Procedures
The responses to each open-ended question (questions 39-40) were reviewed and organized
into themes agreed upon by both investigators. Common themes were recognized in responses
and investigators tallied each time a theme recurred. Responses from questions 39 and 40 were
each coded as “comments of support” or “comments of concern” or, in some cases, both.
Comments of support were further divided and coded into seven themes for question 39 and
five themes for question 40. Comments of concern were further divided and coded into six
themes for question 39 and four themes for question 40.

Results
Demographics
Study participants were predominantly female (87%, n=47/54). Approximately half of
participants were genetic counselors (48%, n=26/54) and the rest was comprised principally of
social workers (22%, n=12/54) and neurologists (17%, n=9/54). Most of these providers (87%,
n=47/54) reported seeing 1-5 patients per month for predictive testing for HD. Geographically,
37% (n=20/54) of participants are currently practicing on the East Coast, 31% (n=17/54) in the
Midwest, 17% (n=9/54) in the South, and 15% (n=8) on the West Coast. Participants were an
experienced group: 57% (n=31/54) were age 41 or older, and most have been practicing as a
healthcare provider for greater than 10 years (61%, n=33/54). A majority (54%, n=29/54) have
been involved with HD predictive testing for 5 years or more. Complete study demographics can
be found in Table 1.
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Table 1. Demographics
Gender
Female
Male
Age
21-25
26-30
31-35
36-40
41+
Region
East Coast
Midwest
South
West Coast
Role
Genetic Counselor
Neurologist
Nurse Practitioner
Psychiatrist
Other
Years of Practice
< 5 years
5-10 years
> 10 years
Years of Experience with HD Predictive Testing
< 5 years
5-10 years
> 10 years

n

%

47
6

87%
11%

1
3
11
8
31

2%
6%
20%
15%
57%

20
17
9
8

37%
31%
17%
15%

26
9
2
2
3

48%
17%
4%
4%
6%

7
14
33

13%
26%
61%

25
8
21

46%
15%
39%

Are Providers Making the Switch?
Asked about practice at their institution prior to 2016, 54% (n=29/54) of respondents
reported that they had been following the HDSA-recommended 3-visit protocol whereas 33%
(n=18/54) of respondents reported following a 2-visit protocol. The remainder of respondents
(13%, n=7/54) were unsure of the protocol used by their respective testing center or followed
alternative protocols, including one 4-visit and one 5-visit protocol. After the guidelines changed
in 2016 to a recommended 2-visit protocol, 37% (n=20/54) of respondents reported making the
switch. No respondents who were using a 2-visit protocol prior to 2016 reported any change in
practice.
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A majority of respondents (63%, n=34/54) reported that their center’s protocol remained
unchanged in light of the HDSA’s updated recommendations. A significant portion of providers
who reported no change in practice were already following their own 2-visit protocol (44%,
n=15/34). The remaining 29% (n=10/34) continued to follow the 3-visit protocol, and 24%
(n=8/34) are not following either of the two recommended protocols.

Workload
Of the 20 respondents who reported that their center changed their protocol in light of
the HDSA’s updated recommendations (37%, n=20/54), more than half (65%, n=13/20) reported
that since the change in protocol, the number of individuals choosing to undergo predictive
testing for HD has not changed, while 35% (n=7/20) of this group reported that this number has
increased. Of participants who switched, 60% (n=12/20) reported that the amount of interaction
they have with patients did not change, whereas 20% (n=4/20) reported an increase and 20%
(n=4/20) reported a decrease. Additionally, the change in protocol did not change the amount of
time providers spent interacting with other providers according to 80% (n=16/20) of respondents
who switched. Most participants who reported switching to the 2-visit protocol after 2016
indicated that their institution continued to use the new 2-visit protocol at the time of this study
(85%, n=17/20).

Emotional Burden
A significant portion of providers reported an emotional burden related to their work with
predictive testing for HD (48%, n=26/54). The most frequent types of emotional burden cited by
participants were “emotional overextension” (62%, n=16/26) and “exhaustion” (27%, n=7/26). A
complete list of the types of emotional burden examined is listed in Table 2.
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There was no difference in the emotional burden reported by providers who made the
protocol switch and providers who did not. Furthermore, there was no difference in the type of
emotional burden cited between those who have continuously followed the 2-visit protocol or the
3-visit protocol. However, those who switched to a 2-visit protocol were more likely to cite
“feelings of lack of achievement” (12%, n=3/26) than those who did not. Of those who reported
making the protocol switch after 2016, most (83%, n=10/12) reported that there was no change
in their feelings of emotional burden. One provider (8%, n=1/12) reported increased emotional
burden after the switch in protocols. None of the respondents reported that the switch in
protocols decreased their feelings of emotional burden.

Table 2. Measure of emotional burden in HD predictive testing providers.
Feeling of Emotional Burden

# of Respondents

Emotional overextension

62% (n=16/26)

Exhaustion

27% (n=7/26)

Feelings of lack of achievement 12% (n=3/26)
Impersonal feelings

8% (n=2/26)

Depersonalization of work

8% (n=2/26)

Incompetence at work

0% (n=0/26)

Provider Opinions on Protocols
When asked whether or not they feel it is important to follow a protocol, 96% of
respondents (n=52/54) said yes, and when asked whether or not it should be the same protocol
for each patient, 41% (n=22/54) said no. Participants were also asked to comment on which
protocol they believed patients prefer and 72% of respondents (n=39/54) reported that patients
prefer the 2-visit protocol. Overall, 54% of respondents (n=29/54) reported a personal
preference for the 2-visit protocol.
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When asked to share any additional thoughts or concerns about the 2-visit protocol,
comments were coded by investigators as “comments of support” or “comments of concern” or,
in some cases, both. Of the 42 total comments regarding this protocol, 48% (n=20/42) were
comments of support and 74% (n=31/42) were comments of concern. The most frequently
noted comments of support were coded as “flexibility to add sessions as needed” (25%,
n=5/20), “improves patient autonomy” (20%, n=4/20), and “accommodates long-distance
patients” (20%, n=4/20). Of the comments of concern, 39% (n=12/31) were coded as
“insufficient time to reconsider decision,” 19% (n=6/31) were coded as “lack of provider
reimbursement for required telephone counseling,” and another 19% (n=6/31) were coded as
“additional workload.” A complete list of coded comments regarding the 2-visit protocol can be
found in Tables 3A and 3B.

Table 3A. Comments of support for the 2-visit protocol.
Comments of Support

Number of Respondents

Flexibility to add sessions as needed

25% (n=5/20)

Improves patient autonomy

20% (n=4/20)

Accommodates long distance patients

20% (n=4/20)

Less “push back” from patients

10% (n=2/20)

Saves patients time and money

10% (n=2/20)

Allows for collaboration with other providers

5% (n=1/20)

Stops patients from seeking testing through “faster” source 5% (n=1/20)
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Table 3B. Comments of concern for the 2-visit protocol.
Comments of Concern

Number of
Respondents

Insufficient time to reconsider decision

39% (n=12/31)

Lack of provider reimbursement for required telephone
counseling

19% (n=6/31)

Additional workload

19% (n=6/31)

Insufficient time to make insurance considerations

10% (n=3/31)

Less face-to-face counseling

3% (n=1/31)

Lack of autonomy

3% (n=1/31)

When asked to share any additional thoughts or concerns about the 3-visit protocol,
comments were again coded by investigators as “comments of support” or “comments of
concern” or, in some cases, both. Of the 36 total comments regarding this protocol, 28%
(n=10/36) were comments of support and 75% (n=27/36) were comments of concern. Of the
reported comments of support, 50% (n=5/10) were coded as “sufficient time to establish
rapport.” Of the reported comments of concern, 52% (n=14/27) were coded as “too burdensome
for everyone involved” and 37% (n=10/27) were coded as “unnecessary number of visits.” A
complete list of coded comments regarding the 3-visit protocol can be found in Tables 4A and
4B.
Table 4A. Comments of support for the 3-visit protocol.
Comments of Support

Number of Respondents

Sufficient time to establish rapport

50% (n=5/10)

Patients appreciate thorough process

20% (n=2/10)

Sufficient time to make insurance considerations 10% (n=1/10)
Less telephone counseling required

10% (n=1/10)

Decades of experience prove protocol’s success 10% (n=1/10)
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Table 4B. Comments of concern for the 3-visit protocol.
Comments of Concern

Number of Respondents

Too burdensome for everyone involved

52% (n=14/27)

Unnecessary number of visits

37% (n=10/27)

Patients may seek “faster” sources of testing 7% (n=2/27)
Lack of patient autonomy

4% (n=1/27)

Discussion
Our study provides considerable evidence that the 2-visit protocol for HD predictive
testing has been widely adopted by practicing providers. One third of the participants in this
study had already been following a 2-visit protocol prior to 2016 despite the fact that HDSA at
that time recommended three visits, and more than half of those who were not previously using
a 2-visit protocol made the switch after 2016 when the HDSA guidelines were amended. This
means that 70% of participating providers are currently using the 2-visit protocol.
Although a majority of providers use the 2-visit protocol, some concerns about this
protocol were reported in the open-ended responses to our survey. A majority of participants
believed the 2-visit was most preferred by patients and over half reported a preference for the 2visit protocol overall. Still, when asked to make any additional comments about the 2-visit
protocol, a majority of these comments were concerns. Of all the comments for this protocol,
one of the concerns expressed most frequently (39%) was that patients would not have enough
time to reconsider their decision to undergo testing before receiving results. Another frequently
cited concern (19%) was related to lack of provider reimbursement for the extra telephone
counseling that would be required due to the omission of a third visit. Some commenters (19%)
also expressed concern about additional burden that would be placed on providers related to
the 2-visit protocol. Notably, these concerns came primarily from commenters who have not
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made the switch to the 2-visit protocol. Commenters who reported having not made the switch
to the 2-visit protocol (33%, n=12/36) were three times as likely to report comments of concern
than commenters who report currently using the 2-visit protocol (11%, n=4/36). Data from our
study shows that the majority of providers who made the switch in protocols are not
experiencing a change in workload, as suggested by the following statistics: 65% of providers
who changed protocols reported no change in or decreased number of individuals choosing to
undergo predictive testing, 60% report no change in or decreased interaction with patients
undergoing testing, and 80% report no change in or decreased amount of time spent interacting
with other providers. These numbers suggest that hypothetical concerns about increased
provider workload may not be the experience of those who have made the switch.
Respondents also offered several reasons to support the 2-visit protocol. The majority of
these comments were centered around improving the overall testing experience for the patient.
Commenters reported that the 2-visit protocol allows for greater patient autonomy by allowing
an individual to proceed with predictive testing after the initial in-person visit if they choose to do
so. Many commenters also expressed support for the flexibility of this protocol, citing the ability
to add additional counseling sessions if necessary. One commenter stated, “I look at the
protocol as a minimal standard, not a limit as to what can be done.” Additionally, commenters
reported support for this protocol for its increased accessibility to patients traveling long
distances for this testing. This makes sense given there are relatively few HD Centers of
Excellence in comparison with the at-risk population and traveling to one of these centers for
several visits may not be feasible for some individuals. Notably, these supportive comments
came primarily from providers who are currently using the 2-visit protocol. Commenters who
reported use of the 2-visit protocol (56%, n=20/36) were about seven times as likely to report
comments of support than commenters who reported not having made the switch to the 2-visit
protocol (8%, n=3/36). This further supports our observation that providers overall are
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embracing the 2-visit protocol and that the concerns for this protocol are coming from providers
who have not had firsthand experience with the switch.
In regard to the 3-visit protocol, commenters noted much more concern (75%) than
support (28%). While one provider argued that decades of experience prove the success of the
3-visit protocol, over half of commenters remarked that the 3-visit protocol is too burdensome for
everyone involved, and 37% of commenters agreed that three visits is simply unnecessary.
The ratio of negative to positive comments was higher for the 3-visit protocol (2.7:1) but
both protocols drew more negative than positive comments, highlighting the difficulty in a onesize-fits-all solution. While 96% of providers agree that following a protocol is important, a
significant portion (41%) do not feel the same protocol should be followed for each patient.
Several providers remarked in the free response section that protocols should be patientspecific and done on a case by case basis. It was suggested by one provider that rather than
implementing a mandatory pre-test protocol, providers should instead implement a mandatory
post-test assessment of need for follow-up care. This post-test protocol was theorized by the
provider as being more beneficial to the well-being of the individual. A few providers also said
that “the protocols are good guidelines but each clinic should be able to make variations at their
own discretion.” Overall, the responses suggest that while the protocols are good starting
points, providers should have the flexibility to adapt to each patient’s specific needs in the
predictive testing process.
Prior to this study, we hypothesized that the change in protocol would have a negative
impact on provider burden by increasing workload and psychological distress. However, no
evidence was gathered to suggest that the 2-visit protocol has caused an increase in provider
workload. In regard to emotional burden, our data shows that there is no difference in the
emotional burden reported by providers who made the protocol switch and providers who did
not. Results from this study do however suggest high emotional burden for this type of work,
regardless of the protocol. 48% of providers reported feeling emotionally burdened by their
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involvement in the predictive testing process. Of those who reported emotional burden, the most
commonly cited evidence of burnout was emotional overextension (62%) and exhaustion (27%).
Further studies are needed to assess emotional burden in more detail.
Interestingly, a large portion (61%) of the providers who completed the survey reported
having been practicing for over 10 years, but 46% have less than 5 years of experience with the
predictive testing for HD process. We theorize two possible explanations for the lack of
experienced providers. First, the amount of emotional burden endured by genetic service
providers during this process is so great that there is a high rate of burnout. This may lead to a
high level of employee turnover. Secondly, the lack of experience may be due to an increase in
demand of individuals looking to pursue predictive testing. In this case, providers are becoming
involved to help mitigate the surge in demand. Another possibility is that this line of work is
demanding and does not tend to be done by inexperienced counselors. Further studies would
be necessary to explore this topic.
Our study had several limitations. First, our sample size was small (n=54), as it was tied
to the limited number of HDSA approved HD Centers of Excellence. All 43 designated centers
as well as six recognized partner centers received invitations to participate, but in order to
preserve as much anonymity as possible, providers did not report which center they were from.
Although we have a fairly even distribution across regions, we are unable to determine how
many centers are represented. In addition, not all of the participants responded to the entire
survey. These responses were eliminated from the final data set, reducing the total number of
responses. Second, although we asked providers who did not make the switch in protocols
questions about how the switch would have affected their overall burden, these responses were
speculative and have limited value. Similarly, we were not able to directly assess patients’
experience with decisional regret and responses from providers may not accurately reflect the
opinions of patients.
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Ideal future research into the patient experience should involve a prospective
longitudinal study with two groups of study participants: patients who go through testing using a
3-visit protocol and patients who go through predictive testing using the 2-visit protocol. This
would allow researchers to assess directly the impact on the individual, both positive and
negative, of each protocol.

Conclusion
This study demonstrates that a 2-visit protocol for HD predictive testing has been widely
adopted following the HDSA’s 2016 update to their guidelines. While respondents had concerns
about this protocol, our study did not show that making the switch had any impact, positive or
negative, on the burden of participating providers related to workload or emotional burden.
However, our results do suggest a high emotional burden related to this type of work, regardless
of the type of protocol, a topic that has not been investigated previously. We propose that future
research include longitudinal studies of the patient’s experience of this process.
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APPENDIX
Appendix A. Complete copy of the participant questionnaire.
Q1. What best describes your gender?
Male
Female
Choose not to say
Q2. What is your age?
21-25
26-30
31-35
36-40
41+
Q3. Which geographical region best describes your primary work location?
East Coast
West Coast
Midwest
South
Q4. What best describes your role as a healthcare provider?
Genetic Counselor
Neurologist
Psychiatrist
Social Worker
Nurse Practitioner
Other (please specify)
Q5. How many years have you practiced as a healthcare provider?
Less than 5 years
5-10 years
Greater than 10 years
Q6. Do you currently work, or have you in the past worked, with patients participating in
predictive genetic testing for HD?
Yes
No
Q7. How many years of experience do you have working with predictive genetic testing for HD?
Less than 5 years
5-10 years
Greater than 10 years
Q8. On average, how many patients does your clinic currently see for predictive genetic testing
for HD in one month?
Q9. Select all of the following healthcare providers that you work with during the predictive
testing protocol for HD (include your own role).
Genetic counselor
Neurologist
Nurse practitioner
Psychiatrist
Social worker
Other (please specify)
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Q10. Do you feel your clinic has enough providers available to meet the demand of patients
choosing to undergo predictive testing?
Yes
No
Q11. Prior to 2016, which model of testing did your clinic follow?
2-visit
3-visit
Other (please specify)
Q12. Since 2016, has your clinic changed the protocol for predictive testing in HD?
Yes
No
For those who answered yes:
Q13. Currently, which model of testing does your clinic follow?
2-visit
3-visit
Other (please specify)
Q14. Since your clinic’s change in predictive testing protocol, how has the number of individuals
choosing to undergo testing been affected?
Increased
Decreased
No change
Q15. Since your clinic’s change in predictive testing protocol, how has the amount of interaction
you have with other predictive testing providers been affected?
Increased
Decreased
No change
Q16. Since your clinic’s change in predictive testing protocol, how has the quality of interaction
you have with other predictive testing providers been affected?
Better
Worse
About the same
Q17. Since your clinic’s change in predictive testing protocol, how has the amount of interaction
you have with individual predictive testing patients been affected?
Increased
Decreased
No change
Q18. Since your clinic’s change in predictive testing protocol, how has the quality of interaction
you have with individual predictive testing patients been affected?
Better
Worse
About the same
Q19. What changes have you observed in terms of the number of individuals experiencing
decisional regret? (Decisional regret is defined as feelings of regret or remorse felt after a health
care decision is made)
Increased
Decreased
No change
Q20. Does your role in the predictive genetic testing protocol for HD affect your personal
emotional burden?
Yes
No
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Q21. Select all of the following that you have experienced as a result of working with the
predictive testing protocol for HD:
Emotional overextension
Exhaustion
Impersonal feelings
Depersonalization of work
Incompetence at work
Feelings of lack of achievement
Q22. How has the level of your personal emotional burden been affected? (Emotional burden is
defined as the feeling of being emotionally stressed, sometimes in the form of feeling the pain of
others or feeling inner guilt)
Increased
Decreased
No change
For those who answered no:
Q23. Currently, which model of testing does your clinic follow?
2-visit
3-visit
Other (please specify)
Q24. In your opinion, how would a change in your clinic’s predictive testing protocol affect the
number of individuals choosing to undergo testing?
Increase
Decrease
No change
Q25. In your opinion, how would a change in your clinic’s predictive testing protocol affect your
workload as a provider?
Increase
Decrease
No change
Q26. In your opinion, how would a change in your clinic’s predictive testing protocol affect the
amount of interaction you have with other predictive testing providers?
Increase
Decrease
No change
Q27. In your opinion, how would a change in your clinic’s predictive testing protocol affect the
quality of interaction you have with other predictive testing providers?
Better
Worse
About the same
Q28. In your opinion, how would a change in your clinic’s predictive testing protocol affect the
amount of interaction you have with individual predictive testing patients?
Increase
Decrease
No change
Q29. In your opinion, how would a change in your clinic’s predictive testing protocol affect the
quality of interaction you have with individual predictive testing patients?
Better
Worse
About the same
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Q30. In your opinion, how would a change in your clinic’s predictive testing protocol affect the
number of individuals who experience decisional regret? (Decisional regret is defined as
feelings of regret or remorse felt after a health care decision is made)
Increase
Decrease
No change
Q31. Does your role in the predictive genetic testing protocol for HD affect your personal
emotional burden?
Yes
No
Q32. Select all of the following that you have experienced as a result of working with the
predictive testing protocol for HD:
Emotional overextension
Exhaustion
Impersonal feelings
Depersonalization of work
Incompetence at work
Feelings of lack of achievement
Q33. In your opinion, how would a change in your clinic's predictive testing protocol affect these
feelings for you personally?
Increase
Decrease
No change
Q34. Do you feel it is important to follow a protocol for predictive genetic testing in HD?
Yes
No
Q35. Do you feel it is important to follow the same protocol for predictive genetic testing in HD
for each patient?
Yes
No
Q36. In your opinion, which protocol do you believe provides the best patient care?
2-visit
3-visit
Other (please specify)
Q37. In your opinion, which protocol do you believe patients prefer?
2-visit
3-visit
Other (please specify)
Q38. Which protocol do you prefer overall?
2-visit
3-visit
Other (please specify)
Q39. What additional comments/concerns do you have regarding the 2-visit protocol? [Eg.
anything you particularly like or disagree with]
Q40. What additional comments/concerns do you have regarding the 3-visit protocol? [Eg.
anything you particularly like or disagree with]
Q41. Please use this space for any further comment on predictive genetic testing protocols for
HD.
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